EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Recruiting · NCT07262619 · Registry updated 2026-09-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, mismatch repair cancer syndrome 1, neoplasm, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07262619 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eikon Therapeutics | 7 |
| Merck Sharp & Dohme LLC | 650 |
35 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.